CALC supply chain intelligence for CalciMedica, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CalciMedica, Inc. (CALC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | 90% | The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the precl… |
| VENDORS | VENDORS | 90% | The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the precl… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CALC graph: vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treat… |
| MYGN | Myriad Genetics, Inc. | 72% | vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide heal… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CALC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CALC graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide heal… |
| CALCIMEDICA-SUBSIDIARY-INC | CALCIMEDICA-SUBSIDIARY-INC | 62% | 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November … |
| CALM | Cal-Maine Foods, Inc. | 62% | Reciprocal relationship from CALM graph: Reciprocal relationship from CALC graph: Reciprocal relationship from CALM graph: Reciprocal relationship from CALC graph: Reciprocal relationship from CALM g… |
| CELLECT-LLC | CELLECT-LLC | 62% | vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide heal… |
| GRAYBUG-CAMARO-MERGER-SUB-INC | GRAYBUG-CAMARO-MERGER-SUB-INC | 62% | 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November … |
| GRAYBUG-VISION-INC | GRAYBUG-VISION-INC | 62% | 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November … |
| SG-DAN-EQUITY-HOLDINGS-LLC | SG-DAN-EQUITY-HOLDINGS-LLC | 62% | s. If a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CALC-DEBT-3732 | Warrants outstanding: 216000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| CALC-DEBT-3733 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| CALC-DEBT | Debt stack $6.7M | 90% | Market cache reports total debt of $6.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CALC-OWNER-DEERFIELD-MANAGEMENT-COMPANY-L-P | Deerfield Management Company, L.P | 95% | 13F/ownership overlay lists Deerfield Management Company, L.P; shares held 1,300,000; ownership 22.96%; value $810,680; as of 2025-09-30. |
| CALC-OWNER-SOLEUS-CAPITAL-MANAGEMENT-L-P | Soleus Capital Management, L.P. | 95% | 13F/ownership overlay lists Soleus Capital Management, L.P.; shares held 683,904; ownership 12.08%; value $426,482; as of 2025-09-30. |
| CALC-OWNER-AISLING-CAPITAL-MANAGEMENT-LP | Aisling Capital Management LP | 95% | 13F/ownership overlay lists Aisling Capital Management LP; shares held 521,114; ownership 9.20%; value $324,966; as of 2025-09-30. |
| CALC-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 98,852; ownership 1.75%; value $61,644; as of 2025-09-30. |
| CALC-OWNER-MERITAGE-PORTFOLIO-MANAGEMENT | Meritage Portfolio Management | 95% | 13F/ownership overlay lists Meritage Portfolio Management; shares held 61,539; ownership 1.09%; value $38,375; as of 2025-12-31. |
| CALC-OWNER-STONEHAGE-FLEMING-FINANCIAL-SERVICES-HOL | Stonehage Fleming Financial Services Holdings Limited | 95% | 13F/ownership overlay lists Stonehage Fleming Financial Services Holdings Limited; shares held 53,703; ownership 0.95%; value $33,489; as of 2025-12-31. |
| CALC-OWNER-ENVESTNET-ASSET-MANAGEMENT-INC | Envestnet Asset Management Inc. | 95% | 13F/ownership overlay lists Envestnet Asset Management Inc.; shares held 76,705; ownership 1.35%; value $47,833; as of 2025-09-30. |
| CALC-OWNER-RENAISSANCE-TECHNOLOGIES-LLC | Renaissance Technologies, LLC | 95% | 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 70,000; ownership 1.24%; value $43,652; as of 2025-09-30. |
| CALC-OWNER-SHEETS-SMITH-INVESTMENT-MANAGEMENT | Sheets Smith Investment Management | 95% | 13F/ownership overlay lists Sheets Smith Investment Management; shares held 51,100; ownership 0.90%; value $31,865; as of 2025-09-30. |
| CALC-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 407,801; ownership 7.20%; value $254,304; as of 2025-12-31. |
| CALC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 30 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 |